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S u m m a r y  
 
It is our intention to present in this work indications, 
contraindications and benefits regarding the application of 
therapeutic hypothermia in patients after cardiac arrest. 
Therapeutic hypothermia means lowering the internal 
temperature of the human body to 32-34 degree Celsius. It is 
a safe and efficient method increasing the patients’ chances 
of survival and their neurological prognosis, especially if the 
arrest was caused by cellular rhythm disorders. The 
efficiency of this treatment is confirmed by the American 
Heart Association and the European Resuscitation Board, 
which included it in the resuscitation guidelines for adults. 
We also describe the place of this treatment in valid 
resuscitation guidelines and pay attention to its mostly 
unknown potentialities and a few controversies.  
 
 
S t r e s z c z e n i e  
 
W pracy chcielibyśmy dokładnie przedstawić wskazania, 
przeciwwskazania oraz korzyści ze stosowania hipotermii 
terapeutycznej w leczeniu pacjentów po zatrzymaniu 
krążenia z przyczyn kardiologicznych.  
Hipotermia terapeutyczna to obniżenie wewnętrznej 
temperatury ciała do 32-34 stopni Celcjusza. Jest to 
bezpieczna i efektywna metoda zwiększająca szansę na 
przeżycie oraz poprawiająca prognozy neurologiczne. 
Skuteczność tej metody jest potwierdzona przez  Amerykań-
skie Towarzystwo Kardiologiczne oraz Europejską Komisję 
Resustytacyjną i została ona wprowadzona do wytycznych 
resustytacji dla dorosłych.  
Przedstawiamy również miejsce hipotermii terapeu-
tycznej w świetle aktualnych wytycznych dotyczących 
resuscytacji, a także wskazujemy nowe, nieuwzględnione 
jeszcze potencjalne możliwości oraz nieliczne wątpliwości 
towarzyszące stosowaniu tej metody leczenia.    
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Therapeutic hypothermia used in patients after 
sudden circulation arrest is a safe and efficient method 
increasing the patients’ chances of survival and  their 
neurological prognosis, especially  if  the  arrest  was 
 
 
caused by cellular rhythm disorders. The efficiency of 
this treatment is confirmed by the American Heart 
Association and the European Resuscitation Board, 
which included it in the resuscitation guidelines for 
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adults. However, it does not seem to be so certain in 
the case of patients in a state of pulseless electrical 
activity. 
Hypothermia means decreasing the internal body 
temperature below 35 degree Celsius. Its theoretical 
basics were developed in the 1950s, when an Austrian 
anaesthesiologist of Czech descent published his book 
‘ABC of Resuscitation’. In the age of evidence-based 
medicine (EBM) we regard research of Australian 
scientists headed by Stephen A. Bernard, published in 
2002 [1], and European ones headed by Michael 
Holzer [2] to be pioneers in that regard. 
In the above research participated over 200 patients 
after sudden cardiac arrest (SCA) in the ventricular 
fibrillation or ventricular tachycardia mechanisms 
(VF/VT). Another inclusion criteria in the research was 
the hemodynamic stability of the patients after the 
successful reanimation in the condition of a coma (< 8 
point on the Glasgow Coma Scale). Exclusion criteria 
were: presence of cardiogenic shock with the average 
blood pressure <60 mm Hg, hypoxemia, coma 
resulting from other causes than SCA, terminal disease, 
pregnancy or coagulopathy. The authors were the first 
to prove the decrease in mortality and adverse 
neurological changes in cardiac-arrest patients with VF 
or VT mechanisms treated by mild therapeutic 
hypothermia. On that basis this treatment became a 
standard procedure in treating SCA patients.  
 
THERAPEUTIC HYPOTHERMIA APPLICATION 
PROTOCOL 
 
Therapeutic hypothermia means lowering the 
internal temperature of the human body to 32-34 
degree Celsius. It is composed of four stages: initial 
induction stage, sustaining stage, passive warming 
stage and normothermia stage.  
The induction stage is cooling down the patient’s 
body as soon as possible using various methods (table 1).  
All the above methods are regarded as safe and 
efficient. However, invasive ones are quicker than the 
non-invasive ones. It is especially recommended and 
used widely in the pre-hospital care to inject NaCl 
solution cooled down to the temperature of 4 degree 
Celsius (0.9%  NaCl solution, dosage 30 ml/kg mc 
[3]).  
During the hypothermia sustaining stage the 
patient’s body is maintained in the target temperature 
for 12 to 24 hours. During the passive warming stage 
the internal body temperature is slowly raised, not 
quicker than 0.2 to 0.5 degree Celsius an hour. The last 
stage is to fight the fever, which can accompany this 
procedure and preventing the temperature from raising 
above 37 degree Celsius for the next 24 hours.  
 
Table I. Induction stage – methods 
Tabela I. Etapy indykcji hipotermii – metody 
 
Hypothermia induction (indukcja hipotermii) 
Noninvasive methods  
(metody nieinwazyjne) 
Invasive methods  
(metody inwazyjne) 
Ice bags (worki z lodem) Injecting cold fluids to peripheral 
or central veins 
(iniekcja zimnych płynów do 
obwodowego bądź centralnego 
układu żylnego) 
Cooling blankets with cold water 
circulation  
( chłodzące okrycia z zimnym 
obiegiem wody) 
Rinsing body cavities, bladder, 
anus 
Opłukiwanie jam ciała, pęcherza 
moczowego, odbytnicy 
Cooling blankets with cold air 
circulation  





THERAPEUTIC HYPOTHERMIA SAFETY 
 
Hypothermia complications in clinical research 
were relatively rare [4]. Those most often described in 
literature are: enlarged diuresis, vulnerability to 
infections (pneumonia, sepsis), dyselektrolitemia 
(hypomagnesemia, hypopotasemia), rhythm 
abnormalities (most often ventricular fibrillation with 
slow ventricular functionality, ventricular rhythm 
abnormalities), slow heart rate, muscle tremors, 
decreased heart projection (CO), clinically 
recognizable as lung edema, hypoglycaemia, 
thrombocytopenia, coagulation complications and 
disturbed medicine clearance. In Bernard’s work the 
frequency of complications was not seriously greater in 
the group of patients treated with hypothermia than in 
the control group [1].  
Moreover, it was observed during the research that 
in the group treated with hypothermia the end point 
(demise) occurred in 41% of patients, whereas in the 
group treated in the standard way it was 55% (p=0.02). 
Neurological complications in SCA patients with 
ventricular rhythm abnormalities were also more often 
in the control group (61% versus 45%, p=0.009) [2]. 
In another research it was noticed that patients 
undergoing the hypothermia had more chances of 
survival and less neurological complications, as well as 
spent less time in the intensive care unit – on the 
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average by 7 days – and did not require as much 
artificial ventilation [5]. 
Recently published research of German authors 
also confirmed the benefits of using therapeutic 
hypothermia on patients suffering from heart attack 
with ST–segment elevation. However, no increased 
mortality in the 30-day-period was observed, with 
statistically negligible tendency towards lesser long-
term death rate during one-year period and noticeably 
improved neurological prognosis evaluated according 
to the Cerebral Performance Category (CPC) [6]. 
 
PLACE OF HYPOTHERMIA TREATMENT IN THE 
LIGHT OF CURRENT GUIDELINES 
 
In the current European guidelines of 2010 
therapeutic hypothermia is recommended as a routine 
procedure for all SCA patients, both in the case of 
ventricular heart rhythm abnormalities subject to 
defibrillation and in the pulseless electrical activity [7]. 
There is some difference between the guidelines of the 
European Resuscitation Board and those of the 
American Heart Association (AHA). In the latter, 
patients who in out-of-hospital conditions had cardiac 
arrest as a result of ventricular fibrillation or 
ventricular tachycardia should be treated with 
therapeutic hypothermia (recommended grade I, 
evidence level B). Patients with out-of-hospital SCA, 
with the pulseless electrical activity (PEA) or the 
asystole can be, according to the guidelines, treated 
with hypothermia to reduce neurological 
complications. However, in that case the recommended 
grade is much lower (IIb, evidence level B) [8]. The 
application of hypothermia for patients after the 
cardiac arrest in hospital has similarly low level of 
recommendations according to the AHA.  
Published research evaluating the efficiency and 
safety of treating with hypothermia SCA patients with 
severe coronary syndromes confirms its benefits in 
preventing neurological complications and prognosis 
improvements [6, 9, 10, 11]. In Götberg's research  
patients with an acute STEMI eligible for primary PCI  
within 30 minutes their body temperatures were cooled 
to the target temperature of <35°C without allowing 
the induction of cooling to interfere with or prolong the 
door-to-balloon time for percutaneous coronary 
intervention (door-to-balloon time was 43±7 minutes 
in the hypothermia group and 40±6 minutes in the 
control group). Despite similar duration of ischemia, 
infarct size normalized to myocardium at risk was 
reduced by 38% in the hypothermia group compared 
with the control group measured after 4±2 days in a 
CMR examination. Similarly, there was a significant 
decrease in release of Troponin T in the hypothermia 
group (43 % reduction of peak Troponin T release)  
[12]. 2 patients had ventricular arrhythmia during the 
early post infarction period in the control group, 
whereas none in hypothermia group. No heart failure 
was seen in the hypothermia group and 3 patients in 
the normothermia group had clinical signs of heart 
failure.  
Some investigators suggest that these outcomes 
appear to cardioprotection and prevention of 
reperfusion injury. If these results are confirmed in 
larger trials cooling in STEMI patients will be the first 
widely accepted form of successful controlled 
reperfusion preventing reperfusion injury except for 
hypothermia following cardiac arrest [13, 14].  
The latest guidelines of the AHA dedicated to the 
pre-hospital procedures in case of Adult Advanced 
Cardiovascular Life Support recommend that patients 
after cardiac arrest and successful reanimation are 
directed to reference centres. Such hospitals should 
ensure constant care in the intensive care units, 
including round-the-clock neurological control. They 
should also be prepared to administer invasive 





In spite of many proofs of mild therapeutic 
hypothermia benefits and its safety, there are still 
important unresolved issues of how to apply it. A 
typical example is the presence of ventricular rhythm 
abnormalities. It is known that ischemia, reperfusion, 
and decreasing internal body temperature contribute to 
ventricular rhythm abnormalities. Also, hypothermia 
prolongs the QT corrected interval value or, as 
mentioned, causes or intensifies bradyrhythmia. During 
hypothermia the progression of conduction 
abnormalities may also occur. It is important, because 
basic medications in prevention and treatment of 
ventricular heart rhythm abnormalities, such as beta 
blockers, also slow down heart rate. Amiodaron, often 
used in rhythm abnormalities, also prolongs the QT 
interval value. During the animal research the 
efficiency of this medicine in hypothermia was not 
confirmed [16, 17].  
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Similarly to hypothermia, beta blockers and the 
intravenous application of magnesium used in treating 
ventricular heart rhythm abnormalities in the long QT 
interval cause and intensify both bradyrhythmia and 
conduction disorders. Values of the QT corrected 
interval are in direct proportion to the degree of 
decreased body temperature [18], so in the case of 
ventricular rhythm abnormalities secondary to the 
prolonged QT interval, it is proposed to warm up the 
patient’s body 1 degree Celsius more and inject her 
with magnesium solution [18]. However, there are no 
uniform procedure guidelines based on scientific 
evidence how to monitor and treat ventricular disorders 
during the application of therapeutic hypothermia.  
Another difficult problem is defibrillation and 
medicine action in hypothermia patients. No clinical 
research has been so far made on people to prove their 
efficiency. Experiments on animals gave conflicted 
results, necessitating further research [19, 20].   
Hypothermia changes the metabolism of the whole 
organism, including the clearance of many 
medications, e.g. clopidogrel. In the unique research 
made so far, patients who received saturating dosage of 
clopidogrel (300 do 600 mg) after sudden cardiac 
arrest secondary to the severe coronary syndrome (also 
treated with therapeutic hypothermia), did not undergo 
essential platelet function arrest (defined as platelet 
reactivity index <0.5) during the first 24 hours. On the 
third day, platelet function arrest was achieved in 1/3 
of the patients [21]. Likewise, the safety of using 
double antiplatelet treatment has to be verified through 
big clinical research, as hypothermia increases the risk 
of bleeding, especially in the case of thrombocytopenia 
[2].  
In the light of recently published results of a large 
French SCA patient registry, in the pulseless electric 
activity or asystole mechanisms, the application of 
therapeutic hypothermia became debatable. The 
research included 1145 cases of successful out-of-
hospital reanimation. The percentage of SCA in 
ventricular rhythm abnormalities was 62%, of which 
65% of patients were treated with mild therapeutic 
hypothermia. The research confirmed earlier reports of 
the beneficial influence of hypothermia on mortality 
and neurological complications after SCA. However, 
in the group of SCA patients in the PEA and asystole 
mechanisms no improvement was observed; on the 





Summing up, the application of therapeutic 
hypothermia in patients after sudden cardiac arrest in 
the VF/VT mechanisms is recommended in the light of 
the guidelines of the European Resuscitation Board and 
those of the American Heart Association. Unequivocal 
benefits of that treatment were proved. It is expected 
that further randomized, many-unit clinical research 
will be performed to evaluate its safety and efficiency 
in SCA patients in the OZW mechanism. 
Unfortunately, in Poland therapeutic hypothermia is 
still largely unknown, not only because it is quite 
expensive and difficult to perform, but also because the 
knowledge of this procedure, its potentialities, 
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